Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H16O6 |
Molecular Weight | 388.3695 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1=CC2=C(C=CC=C2)C(CC3=C4C=CC=CC4=CC(C(O)=O)=C3O)=C1O
InChI
InChIKey=WLJNZVDCPSBLRP-UHFFFAOYSA-N
InChI=1S/C23H16O6/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29/h1-10,24-25H,11H2,(H,26,27)(H,28,29)
Molecular Formula | C23H16O6 |
Molecular Weight | 388.3695 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/20826425Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/27064272 | https://www.ncbi.nlm.nih.gov/pubmed/20580560
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20826425
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/27064272 | https://www.ncbi.nlm.nih.gov/pubmed/20580560
Pamoic acid, also called embonic acid, is a naphthoic acid derivative, used as a counter ion of a drug compound to increase the solubility of the drug in water. Pamoic acid has agonist activity for the orphan G protein-coupled receptor GPR35 by which it activates ERK and beta-arrestin2, and causes antinociceptive activity. Although (like other drug salts) it has been considered an inactive compound by the FDA.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1293267 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20826425 |
79.0 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20826425 |
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
A phase II trial with new triptorelin sustained release formulations in prostatic carcinoma. | 2001 |
|
Pharmacokinetic disposition and faecal excretion of pyrantel embonate following oral administration in horses. | 2001 Feb |
|
Chemotherapy of enterobiasis (oxyuriasis). | 2001 Feb |
|
Continuance of studies on Population S benzimidazole-resistant small strongyles in a Shetland pony herd in Kentucky: effect of pyrantel pamoate (1992-1999). | 2001 Jan 20 |
|
Hepatobiliary and pancreatic ascariasis. | 2001 Mar |
|
Vitamin B12 and folic acid in children with intestinal parasitic infection. | 2002 Apr |
|
Ziprasidone and migraine headache. | 2002 Aug |
|
Effects of imipramine on ion channels and proliferation of IGR1 melanoma cells. | 2002 Jul 15 |
|
Strongyloides stercoralis infection with bloody pericardial effusion in a non-immunosuppressed patient. | 2002 Jun |
|
Immediate hypersensitivity reaction associated with the rapid infusion of Crotalidae polyvalent immune Fab (ovine). | 2002 Jun |
|
Synergistic effects of pyrantel and the febantel metabolite fenbendazole on adult Toxocara canis. | 2003 Jul |
|
Anthelmintic treatment in horses: the extra-label use of products and the danger of under-dosing. | 2003 Jun |
|
A modified critical test for the efficacy of pyrantel pamoate for Anoplocephala perfoliata in equids. | 2004 Apr |
|
Schistosomiasis and soil-transmitted helminthiasis: common drugs for treatment and control. | 2004 Feb |
|
Common intestinal parasites. | 2004 Mar 1 |
|
Necator americanus: optimization of the golden hamster model for testing anthelmintic drugs. | 2005 Dec |
|
Management of biliary ascariasis in pregnancy. | 2005 Oct |
|
Cyathostomes in horses in Canada resistant to pyrantel salts and effectively removed by moxidectin. | 2006 Aug 31 |
|
Strongyle egg shedding consistency in horses on farms using selective therapy in Denmark. | 2006 Feb 18 |
|
Coprological study on intestinal helminths in Swiss dogs: temporal aspects of anthelminthic treatment. | 2006 Mar |
|
Comparison of various anthelmintic therapies for the treatment of Trypanoxyuris microon infection in owl monkeys (Aotus nancymae). | 2007 Apr |
|
Field evaluation of the efficacy and the safety of a combination of oxantel/pyrantel/praziquantel in the treatment of naturally acquired gastrointestinal nematode and/or cestode infestations in dogs in Europe. | 2007 Apr 10 |
|
Occurrence of anthelmintic resistant equine cyathostome populations in central and southern Italy. | 2007 Dec 14 |
|
Revalidation and rationale for high pKa values of unconjugated bilirubin. | 2007 May 2 |
|
Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. | 2008 |
|
Anthelmintic prescribing patterns of a sample of general practitioners from selected areas in the colombo district of sri lanka. | 2008 Apr |
|
Influence of Bi 58 Nowy (38% dimethoate) on pyrantel embonate concentration in the liver of rats. | 2009 |
|
The old and new therapeutic approaches to the treatment of giardiasis: where are we? | 2009 |
|
Olanzapine pamoate - blockbuster or damp squib? | 2009 Apr |
|
Field effectiveness of pyrantel and failure of Parascaris equorum egg count reduction following ivermectin treatment in Italian horse farms. | 2009 Apr 6 |
|
Synergistic effect of febantel and pyrantel embonate in elimination of Giardia in a gerbil model. | 2009 Aug |
|
Treatment of naturally occurring, asymptomatic Giardia sp. in dogs with Drontal Plus flavour tablets. | 2009 Aug |
|
Fixed drug eruption resulting from fluconazole use: a case report. | 2009 Jul 6 |
|
Comparison of treatment completion rates for olanzapine pamoate and risperidone microspheres. | 2009 Jun |
|
Second-generation antipsychotic long-acting injections: systematic review. | 2009 Nov |
|
Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection. | 2009 Nov 29 |
|
The control of hookworm infection in China. | 2009 Sep 24 |
|
Diagnosis and control of anthelmintic-resistant Parascaris equorum. | 2009 Sep 25 |
|
Anthelmintic resistance in cyathostomin populations from horse yards in Italy, United Kingdom and Germany. | 2009 Sep 25 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20826425
Abdominal Constriction Test in Mice were used for Pamoic acid activity evaluation. Four groups of 10 male, Swiss-Webster mice (30–35 g; Ace Animals, Inc., Boyertown, PA) were used. They were then injected with saline or one of three doses of pamoic acid disodium (25, 50, and 100 mg/kg s.c.). Twenty minutes later, each mouse was challenged with 0.6% acetic acid (0.30 ml/30 g animal i.p.) and, after an additional 5 min, was observed over the subsequent 10 min for abdominal writhing behavior.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20826425
U2OS cells transiently expressing human GPR35b and _arr2-GFP or HEK 293 cells transiently expressing mouse GPR35 and beta arr2-GFP were used 48 h after transfection. U2OS cells permanently expressing HA-GPR35a and _arr2-GFP (UGPR35_) were used for most experiments. Cells were plated onto coverslips, placed in 24-well plates, and pretreated for 1 h with 0.02 mg/ml poly-Dlysine. Cells were maintained at 37°C in 5% CO2 until ready for experiments (80–85% confluent) and washed once with HBSS before drug application and experiments were performed in HBSS. Agonist stimulated redistribution of _arr2-GFP was assessed after drug treatment for 40 min. Experiments involving antagonist were done with 15 min preincubation of antagonist for both the stable UGPR35 cells and the transiently transfected mouse GPR35 HEK293 cells. To examine reversibility of the antagonist, cells were preincubated with 100 nM CID2745687 for 10 min, then washed with HBSS five times for 5 min each before adding 1 mkM pamoic acid. Cells were then fixed with 4% paraformaldehyde for 20 min at room temperature followed by three washes with HBSS.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:13:16 GMT 2023
by
admin
on
Sat Dec 16 05:13:16 GMT 2023
|
Record UNII |
7RRQ8QZ38N
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m8376
Created by
admin on Sat Dec 16 05:13:18 GMT 2023 , Edited by admin on Sat Dec 16 05:13:18 GMT 2023
|
PRIMARY | Merck Index | ||
|
1493000
Created by
admin on Sat Dec 16 05:13:18 GMT 2023 , Edited by admin on Sat Dec 16 05:13:18 GMT 2023
|
PRIMARY | |||
|
100000079735
Created by
admin on Sat Dec 16 05:13:18 GMT 2023 , Edited by admin on Sat Dec 16 05:13:18 GMT 2023
|
PRIMARY | |||
|
PAMOIC ACID
Created by
admin on Sat Dec 16 05:13:18 GMT 2023 , Edited by admin on Sat Dec 16 05:13:18 GMT 2023
|
PRIMARY | |||
|
7RRQ8QZ38N
Created by
admin on Sat Dec 16 05:13:18 GMT 2023 , Edited by admin on Sat Dec 16 05:13:18 GMT 2023
|
PRIMARY | |||
|
30188
Created by
admin on Sat Dec 16 05:13:18 GMT 2023 , Edited by admin on Sat Dec 16 05:13:18 GMT 2023
|
PRIMARY | |||
|
SUB14746MIG
Created by
admin on Sat Dec 16 05:13:18 GMT 2023 , Edited by admin on Sat Dec 16 05:13:18 GMT 2023
|
PRIMARY | |||
|
8546
Created by
admin on Sat Dec 16 05:13:18 GMT 2023 , Edited by admin on Sat Dec 16 05:13:18 GMT 2023
|
PRIMARY | |||
|
50186
Created by
admin on Sat Dec 16 05:13:18 GMT 2023 , Edited by admin on Sat Dec 16 05:13:18 GMT 2023
|
PRIMARY | |||
|
DTXSID9048984
Created by
admin on Sat Dec 16 05:13:18 GMT 2023 , Edited by admin on Sat Dec 16 05:13:18 GMT 2023
|
PRIMARY | |||
|
130-85-8
Created by
admin on Sat Dec 16 05:13:18 GMT 2023 , Edited by admin on Sat Dec 16 05:13:18 GMT 2023
|
PRIMARY | |||
|
204-998-0
Created by
admin on Sat Dec 16 05:13:18 GMT 2023 , Edited by admin on Sat Dec 16 05:13:18 GMT 2023
|
PRIMARY | |||
|
C004368
Created by
admin on Sat Dec 16 05:13:18 GMT 2023 , Edited by admin on Sat Dec 16 05:13:18 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
NO peak value listed in USP-NF
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|